Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24769550 | 0.83 | DGAT1 (0.37) | NPC1RAB9AENPP2 | |
| SCHEMBL1191784 | 0.82 | ENPP2 (0.39) | NPC1POLBRAB9AENPP2 | |
| SCHEMBL29694733 | 0.82 | ENPP2 (0.39) | NPC1POLBRAB9AENPP2 | |
| SCHEMBL103648 | 0.81 | PTPN1 (0.33) | XDH | |
| SCHEMBL20642467 | 0.77 | DHFR (0.36) | NPC1POLBRAB9AXDH | |
| SCHEMBL389291 | 0.76 | NPC1 (0.31) | NPC1POLBRAB9AXDH | |
| SCHEMBL31281220 | 0.76 | NPC1 (0.31) | NPC1POLBRAB9AXDH | |
| SCHEMBL12689080 | 0.75 | ALDH1A1 (0.38) | XDH | |
| SCHEMBL30859080 | 0.75 | EGFR (0.30) | NPC1POLBRAB9A | |
| SCHEMBL29955101 | 0.75 | ENPP2 (0.44) | NPC1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626112-B2 | Heterocyclic sulfonamide derivative and medicine comprising same | EA PHARMA CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| EP-3101015-B1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | EA PHARMA CO LTD (JP) | 2019-09-18 | — | — | EP | disclosed |
| EP-3101015-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | EA Pharma Co., Ltd. (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-20160332999-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | EA PHARMA CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332999-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | TRPA1, TRPV1, TRPV2 | NPC1 705/4885POLB 4839/4885RAB9A 3760/4885 |
| US-10626112-B2 | Heterocyclic sulfonamide derivative and medicine comprising same | TRPA1, TRPV1, TRPV2 | NPC1 705/4885POLB 4839/4885RAB9A 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.